
Shares of contract development and manufacturing organization (CDMO) firm Cohance Lifesciences fell as much as 6.2% to ₹906 on Thursday. The decline was due to reported block deals that saw around 3.39 crore shares, or 8.9% of the equity, worth around ₹3,073 crore change hands in early trade.
Promoter Jusmiral Holdings offloaded close to 34.1 million shares for around $350 million through block deals, according to a report by CNBC-TV18.
This came just a day after reports suggested Jusmiral was planning to pare up to 5.1% stake in the company, with the transaction size pegged at ₹1,756 crore at a floor price of ₹900 per share, a 6.9% discount to the stock’s last close.
The report added that a 210-day lock-up period has been set for any additional share sales by the promoter. IIFL Capital acted as the book-running lead manager for the transaction.
As of the June quarter, Jusmiral Holdings held a 33.34% stake in Cohance Lifesciences, according to exchange data.
Year-to-date, the stock has declined by over 20%.
Technical View
On the monthly chart, the Cohance stock has been dropping to fresh lows consistently, with the relative strength index (RSI) indicating a sideways trend, noted SEBI-registered analyst Sunil Kotak.
The overall momentum remains bearish, with a strong supply zone at ₹960 - ₹975 and a demand zone at ₹860 - ₹880.
The analyst noted that the stock is lagging behind the broader market and suggested it is best avoided for the time being.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.